For Physicians

The CureMatch Report

The CureMatch report ranks the top 2-, 3-, and 4-drug combination therapy options available for a patient. Standard chemotherapy, targeted therapy, and immunotherapy treatments are also considered and ranked. If desired, specific treatments recommended by the oncologist can also be scored relative to the options that are provided in the CureMatch report.

The report is not a substitute for the physician’s decision, but rather it permits the physician to make the most informed decision, using the most advanced personalized treatment options. The simple report layout and ranking is designed to provide actionable knowledge and insight to the oncologist.

The CureMatch platform takes into consideration activities and toxicities of drugs, and then uses a proprietary rules-based system to rank millions of combinations of drugs and gene aberrations. Priority is given to combinations of drugs covering the highest number of targets, and to combinations using a minimal number of drugs. These criteria are embedded in CureMatch’s Matching Score algorithm calculation, and included on the CureMatch Report.


With millions of possible drug combination options, determining the optimal combination therapy is an extremely daunting task for a physician or tumor board—it is this obstacle to personalized cancer therapy that the CureMatch platform is specifically designed to address.

The CureMatch Process

The CureMatch approach utilizes personalized therapy, in which a solid/liquid biopsy is taken, followed by molecular profiling, and analysis of the data using the CureMatch computational platform. A report is provided to the oncologist that ranks the combination therapy options that are best matched to the patient (or matched monotherapy in cases where there is only a single actionable mutation).

CureMatch itself does not focus on acquisition of genomic and proteomic data or next-generation sequencing (NGS) – it uses other 3rd party companies in this growing molecular profiling market to perform these tests. CureMatch instead focuses on using computation and expertise in oncology, genetics, proteomics, biochemistry, and cell biology to make sense of molecular profiling data, available treatment options, and drug-drug interactions to provide a simple report that ranks the combination therapies that are most likely to be successful.


Obtain genetic profile of the patient’s tumor from any CLIA-approved source, protein expression data (epi)-genetic (deletion, amplification, mutation, and promoter methylation) and expression aberration.



Explore the suitability of approved and investigational drugs, drug Interactions, toxicity & pharmacogenomics knowledge.


CureMatch delivers report that ranks matched combination therapy options to help physicians select therapeutic options.

The CureMatch approach has been used to recommend combination therapy to oncologists treating patients with a variety of cancers.

The CureMatch approach is supported through many recent publications by members of our team.

The CureMatch approach has been supported through studies by our scientists using cancer cell lines.

Therapy routinely used for treatment and/or prevention of other diseases, such as HIV/AIDS, tuberculosis, cardiovascular diseases, diabetes, and Alzheimer’s disease.




The CureMatch approach is based on the several discoveries in clinical cancer genomics. Each discovery is supported by publications from our team.